January 2026 Research Update

Across these papers, researchers focused on tools that could make Behcet's disease easier to monitor over time, especially for intestinal ulcers and eye inflammation. The clearest pattern was that measurements tied to inflammation (on ultrasound or routine blood tests) tended to be higher when disease was active, but many results come from small or single-center studies and need confirmation in larger groups. [1] [2] [3] [4]

For intestinal Behcet's disease affecting the ileocecal area, an intestinal ultrasound score based on bowel wall thickness and blood flow signals was developed and then tested in a separate, prospective group. Using a cutoff score of 16 or higher, the ultrasound score separated active from inactive ulcers compared with colonoscopy, with good sensitivity and specificity in both the development and validation groups. [1]

For Behcet's-related uveitis (eye inflammation), a small case-control study found that the Systemic Immune-Inflammation Index (SII), calculated from a complete blood count, was higher in active uveitis than in inactive disease and healthy controls. A cutoff above 701.72 showed 79.17% sensitivity and 100% specificity in this dataset, suggesting SII may reflect eye-disease activity in some settings. [2]

A separate cross-sectional study looked at the blood test ratio of lactate dehydrogenase (LDH) to albumin and found the ratio was higher in people with Behcet's disease than in healthy controls and increased across severity groups. When used to separate severe from non-severe disease, performance was moderate (area under the curve 0.704), meaning it may not be precise enough on its own for severity tracking. [3]

An exploratory genetic study reported a specific read-through fusion transcript (ATP9A-NFATC2) detected in the blood immune cells of a small group of Behcet's patients and not detected in controls or certain other uveitis types tested. This result points to a possible future biomarker, but it was based on limited numbers and did not test what the fusion does biologically. [4]

Right now, the most near-term relevance is that some monitoring approaches are being studied using tools many clinics already use (ultrasound and routine blood counts), but these results are not the same as a standard, widely adopted test. The intestinal ultrasound score was compared to colonoscopy in a modest-sized development group and a small validation group, and the eye-related blood marker study was small, so it is still uncertain how well these approaches generalize across different hospitals, patient populations, and treatment situations. The genetic fusion-transcript work is earlier-stage and mainly background research until larger studies confirm how specific it is and whether it relates to symptoms or disease activity over time. [1] [2] [3] [4]

Two studies looked at using existing data to help recognize who has Behcet's disease, either from insurance claims or from a mix of clinical and lab features. Overall, they suggest computer-based approaches can sort patients reasonably well within the same healthcare system, but performance depends on what data are available and whether the model has been tested outside the original site. [5] [6]

In a large Japanese claims-data study spanning multiple tertiary hospitals, diagnosis codes alone had very high sensitivity and specificity, but the chance that a person flagged truly had Behcet's (positive predictive value) was more modest. Adding information about specific prescriptions (sulfamethoxazole-trimethoprim and colchicine) improved positive predictive value in both the test set and an external validation hospital. [5]

In a small, single-center study from Saudi Arabia comparing Behcet's disease with rheumatoid arthritis, several machine learning models were tested, and a random forest model reached 97% accuracy with an area under the curve of 1.0 in that dataset. The most influential features included arthritis, oral ulcers, albumin, and anti-DNA antibodies, but the authors noted the work needs external, multicenter validation and could be affected by overfitting. [6]

These papers mainly matter for how researchers study Behcet's disease at a population level and how clinics might, in the future, support diagnostic reasoning using existing records or patterns in routine data. The large claims-based work suggests that combining billing codes with a small amount of medication information can reduce mislabeling in research datasets, while the smaller machine learning study shows what might be possible but is still uncertain without testing in new hospitals and broader patient groups. Neither approach changes what defines a diagnosis in an individual person, because both depend on the quality and completeness of the underlying records. [5] [6]

Across the colchicine-focused papers, the main message was that colchicine was studied not only as a drug choice, but also in terms of how it is prepared and tolerated. In a moderate-sized real-world review, changing from one colchicine form to another was linked with improved overall disease activity and lower blood inflammation markers, but some people stopped due to side effects or lack of benefit. [7]

In 45 people with Behcet's syndrome affecting the mouth/skin and/or joints who had not done well on coated colchicine, switching to a compressed colchicine preparation was linked to better patient and clinician overall disease activity scores, lower C-reactive protein (a blood inflammation marker), and a lower Behcet's Disease Current Activity Index score. Over about 32 months of follow-up on average, 30 people stayed on the compressed preparation, while others discontinued due to adverse events (7) or lack of effect (6). [7]

One case report described a man in his 60s with acute neuro-Behcet's disease and low blood sodium (related to SIADH) whose mucocutaneous symptoms, neurologic symptoms, and low sodium improved while taking colchicine without corticosteroids or other immune-suppressing medicines. Because this was a single patient, it cannot show that the same result would happen for most people with neuro-Behcet's, or that colchicine alone would work in general. [8]

For patients already using colchicine for mouth/skin sores or joint symptoms, these reports mainly add background about two practical questions: whether a different colchicine preparation might be better tolerated or control symptoms better for some people, and whether colchicine alone can ever be enough in complex situations. The preparation-switch data come from a retrospective review (not a randomized trial), and the neuro-Behcet's result comes from one patient, so it remains uncertain how often these outcomes occur and which patients are most likely to benefit. [7] [8]

Across studies of anti-tumor necrosis factor (anti-TNF) medicines in Behcet's disease, the overall direction was toward benefit for severe disease, especially when blood vessels are involved, but the certainty varies because much of the evidence comes from mixed observational studies. Infliximab had high pooled response rates in vascular Behcet's disease, while a single-center cohort comparing infliximab with adalimumab suggested both could work, with differences depending on which organs were affected and how quickly remission occurred. [9] [10]

A systematic review and meta-analysis of 11 studies (284 patients) reported a pooled complete vascular response rate of 78.17% for infliximab in severe and/or refractory vascular Behcet's disease. In subgroup results, remission rates were highest for pulmonary artery aneurysm (99.13%) and were also high for venous thrombosis (86.48%), though the analysis had high between-study differences and limited, uneven safety reporting. [9]

In a retrospective single-center cohort of 87 patients starting their first anti-TNF treatment, initial remission rates were similar for infliximab (75.6%) and adalimumab (78.6%). The study also reported that infliximab reached remission faster in vascular and neurologic disease, while adalimumab was described as providing durable control in mucocutaneous and eye disease; adverse events occurred in about 16% and no severe events were reported. [10]

Safety signals differed in how they were captured: the meta-analysis noted that some included studies reported serious problems like infections (including tuberculosis and disseminated shingles), infusion reactions, and cancers, while the single-center cohort did not report severe events. These differences may reflect different patient populations, monitoring, follow-up time, and reporting methods rather than true risk differences. [9] [10]

These papers are most relevant to people with Behcet's disease affecting blood vessels (such as clots or pulmonary artery aneurysms) or the nervous system, where anti-TNF medicines are often discussed. The pooled infliximab results suggest many patients in prior studies had vascular improvement, but uncertainty remains because the studies varied widely and other treatments were often used alongside infliximab. The infliximab-versus-adalimumab comparison is real-world and not randomized, so differences between groups (such as more vascular disease in the infliximab group) could influence the results, and more consistent safety reporting is still needed. [9] [10]

Across this group of papers, the most serious complications involved inflammation of blood vessels that can affect the brain, large arteries, and internal organs. The strongest signals for severe events came from individual case reports (single patients), while small observational studies suggested possible early or subtle heart and blood vessel changes that do not always cause clear symptoms right away. One article also discussed a future-looking idea for continuously monitoring heart inflammation, but it has not been tested in people with Behcet's disease. [11] [12] [13] [14] [15] [16]

In one case report, an 18-year-old man's first sign of Behcet's syndrome was extensive clotting in several brain veins, causing symptoms like headache and double vision. Follow-up brain imaging showed partial reopening of the blocked veins and his symptoms resolved, showing that serious brain vessel complications can occur even early in the disease. [11]

Another case report described a 37-year-old man who had emergency surgery for a ruptured abdominal aortic aneurysm and later developed a dangerous complication where the aortic graft eroded into the duodenum (part of the small intestine), with active bleeding seen on endoscopy. After repeat graft surgery and duodenal repair, intensified immune-suppressing treatment was followed by no further vascular events in this report, highlighting that major blood vessel disease in Behcet's can interact with surgical materials and lead to severe bleeding. [12]

A third case report linked Behcet's disease to acute kidney inflammation (tubulointerstitial nephritis) with many neutrophils and immune cells in the kidney that stained positive for IL-17A, along with high IL-17A in the blood. The authors reported that the kidney problem improved with Behcet's-directed therapy, suggesting that kidney involvement can be immune-driven during active disease. [13]

Two small cross-sectional studies looked for quieter cardiovascular changes that might relate to longer-term risk. One study found no clear weakening of the main heart pumping chambers, but it did find reduced left atrial strain (a measure of how the heart's upper chamber stretches), which may reflect subtle changes in how the heart fills. [14]

Another cross-sectional pilot study found thicker carotid artery walls on ultrasound and higher blood levels of syndecan-1 in people with Behcet's disease compared with healthy controls; it also found a negative correlation between syndecan-1 and artery wall thickness. Because the study was small and measured markers at one time point, it cannot show whether these differences predict future heart attacks or strokes. [15]

Finally, an editorial proposed implanted sensors near the heart to track swelling, inflammation-related blood markers (like IL-6 and CRP), and pressure changes, with remote monitoring through smartphones. This is a concept piece without patient data, so its safety and usefulness for Behcet's disease complications are unknown. [16]

For patients and caregivers, these papers reinforce that Behcet's disease can sometimes involve serious complications in blood vessels, including clots in brain veins, large-artery problems, and internal bleeding, and it can also involve the kidneys. The case reports show what can happen but cannot tell how common these events are, while the small heart and artery studies mainly serve as background research suggesting there may be subtle cardiovascular changes worth studying further. Technology ideas like implanted monitors are early-stage and not yet part of proven care.

Across these studies, Behcet's disease affected daily life through both symptoms and the surrounding experience of care. People commonly described fatigue and pain as major limits on everyday activities, and many also reported emotional strain, feeling misunderstood, and practical barriers such as treatment side effects and access issues. Overall, the evidence here is exploratory, based on a large patient survey and a small pediatric chart review. [17] [18]

In a multinational survey of 528 people with Behcet's, fatigue, joint pain or swelling, and nervous system symptoms were among the symptoms reported most often, and many participants said these were the symptoms that most affected daily life. Many also felt their fatigue and nervous system symptoms were underestimated by clinicians, and a large proportion reported depression or anxiety. Participants also described treatment challenges, including side effects and stopping treatment due to side effects, along with unmet needs such as better fatigue relief, fewer side effects, and clearer communication and education. [17]

A Colombian study of 15 children and adolescents described how Behcet's can begin early in life and still take years to be diagnosed. Mouth ulcers were reported in all patients, with many also having genital ulcers, joint pain, and nervous system involvement. The study reported a long average delay from first symptoms to diagnosis, and about two-thirds showed clinical improvement during follow-up, but it did not focus on school, social life, or other daily-life measures. [18]

For patients and caregivers, these papers emphasize that day-to-day burden in Behcet's is not only about visible sores or flare-ups: fatigue, pain, and nervous system symptoms can be major drivers of reduced functioning, and emotional distress is common in the surveyed group. They also highlight that side effects and stopping treatments due to side effects were frequent concerns in the survey, and that in children there may be long delays before the condition is recognized. What remains uncertain is how well these results represent all people with Behcet's (the survey relied on self-reports and support-group recruitment, and the pediatric study was small), and which supports most reliably reduce daily-life burden across different patient groups. [17] [18]

Across these papers, the overall pattern is that inherited immune-related genes may influence which protein fragments are shown to immune cells and how strongly immune pathways turn on in Behcet's disease. The evidence is early-stage and does not yet translate into a clinical test, but it helps map which immune signals may be involved. [19] [20]

In a lab-based study using human samples, researchers focused on people who carry HLA-B*51:01 (a genetic marker linked to Behcet's disease). They identified many protein fragments bound to HLA-B*51:01 that were seen only in Behcet's disease, and some of these fragments could activate T cells and increase inflammatory signaling in immune cell tests. [19]

In a genetic study from Denizli, Turkey (88 patients and 133 healthy controls), several variants in IL-12B and IL-23R were more common in people with Behcet's disease, suggesting these immune signaling pathways may contribute to risk in that population. Some links to specific features (such as arthritis, genital lesions, and eye involvement) were reported, but several became less certain after stricter statistical correction, and the study was limited to one region and a modest sample size. [20]

For patients and caregivers, these studies mainly add background about why Behcet's disease can involve an overactive immune response: certain inherited immune genes may shape which targets the immune system reacts to, and which immune pathways are more likely to be activated. This is not yet information that can guide day-to-day care or predict symptoms for an individual person, because the results are exploratory, may vary by ancestry/region, and need confirmation and functional follow-up in larger groups. [19] [20]

Across these papers, a common pattern is that Behcet-like symptoms can have very different underlying causes, including infection, blood and bone marrow disorders, and eye-limited conditions. The reports highlight that the same outward problems (recurrent mouth or genital ulcers, intestinal ulcers, or eye inflammation) do not always point to the same disease, and some mimics improved when care focused on the underlying cause rather than Behcet's itself. Evidence strength ranges from single-patient case reports to a large, single-center eye registry study. [21] [22] [23] [24]

One case described a 33-year-old man whose recurrent mouth and genital ulcers and systemic symptoms initially resembled Behcet's disease but were ultimately linked to active tuberculosis. A pleural biopsy confirmed tuberculosis, and symptoms resolved within four months after anti-tubercular therapy, supporting the idea that infection can sometimes drive a Behcet-like picture. [21]

Two separate case reports described Behcet-like intestinal disease occurring alongside myelodysplastic syndrome (a bone marrow disorder), with trisomy 8 as a key genetic finding. In one patient, intestinal involvement included repeated ileal perforations and improved after corticosteroids and then thalidomide, with both symptom and blood count improvement reported. [23]

In another patient with trisomy 8 associated myelodysplastic syndrome, Behcet-like intestinal disease improved at first with corticosteroids and azacitidine but returned when steroids were reduced, and the care plan emphasized treating the underlying high-risk bone marrow condition. This illustrates that in some people, ongoing inflammation may be tied to the blood disorder itself, not a primary Behcet's diagnosis. [22]

A 10-year registry study of 1,404 patients with ocular inflammation in Taiwan showed that many cases had specific, identifiable causes that are not Behcet's disease. For example, among anterior uveitis cases tested, nearly half had a positive fluid test, most commonly cytomegalovirus, and some needed repeat testing; Behcet's was listed as a relatively uncommon cause among noninfectious panuveitis in this dataset. [24]

For patients and caregivers, these papers mainly serve as background for why doctors may spend time checking for other explanations when symptoms resemble Behcet's, especially with intestinal ulcers or perforations, systemic symptoms that could fit infection, or eye inflammation. The strongest evidence here is about how common different causes of eye inflammation were in one center, while the tuberculosis and myelodysplastic syndrome examples are single-patient reports that may not apply broadly. What remains uncertain is how often these Behcet-like patterns occur in the wider population and which tests or clinical clues best separate Behcet's disease from specific mimicking conditions in day-to-day practice. [21] [22] [23] [24]